BioAlliancePharma announces the launch of Oravig on the US market by its commercial partner, Strativa/Par Pharmaceutical

26-Aug-2010 - USA

BioAlliance Pharma SA announced the launch in the United States of Oravig® (known as Loramyc® in Europe) for the treatment of oropharyngeal candidiasis (OPC) in adults by its commercial partner, Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc.

Oravig® is already available on the US market. The national sales force meeting of Strativa is being held this week in the United States to prepare the promotion of the product to the prescribers.

«The US launch of Oravig® is the ultimate step of a process that confirms our expertise in development and registration of products at the international level. It represents a major achievement that will generate significant revenues for BioAlliance Pharma», declares Dominique Costantini, its CEO. « We are very confident in Strativa sales team’s commitment and know-how to ensure Oravig® success in the US, a product presenting a strong synergy with the product portfolio already commercialized by our US partner».

Other news from the department research and development

More news from our other portals

So close that even
molecules turn red...